STANDARD TREATMENT WORKFLOW (STW)

Rational Use of Topical Medications

Binod K Khaitan¹, Deepika Pandhi², Ananta Khurana³, Dipankar De⁴, Rahul Mahajan⁵, Renu George⁶, Vishal Gupta⁷

¹All India Institute of Medical Sciences, New Delhi; ²University College of Medical Sciences, New Delhi; ³Dr. Ram Manohar Lohia Hospital, New Delhi; ⁴Postgraduate Institute of Medical Education and Research, Chandigarh; ⁵Postgraduate Institute of Medical Education and Research, Chandigarh; ⁶ Christian Medical College, Vellore; ⁷All India Institute of Medical Sciences, New Delhi

CORRESPONDING AUTHOR

Dr Binod K Khaitan, Department of Dermatology, All India Institute of Medical Sciences, New Delhi Email: binodkhaitan@hotmail.com

CITATION

Khaitan BK, Pandhi D, Khurana A, De D, Mahajan R, George R, Gupta V. Rational Use of Topical Medications. Journal of the Epidemiology Foundation of India. 2024;2(1Suppl):S95-S96.


DOI: https://doi.org/10.56450/JEFI.2024.v2i1Suppl.048

This work is licensed under a Creative Commons Attribution 4.0 International License. ©The Author(s). 2024 Open Access

DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.










Standard Treatment Workflow (STW)

RATIONAL USE OF TOPICAL MEDICATIONS



GENERAL PRINCIPLES FOR TCS USE

- Before prescribing, make sure the dermatosis is
- Rule out fungal and bacterial infections at the
- Super potent and potent TCS usually, for a

- resuper potent and potent I/Cs usually, for a maximum duration of 2 weeks
 For children and over face- only low potency TCS
 For larger surface area, use finger tip unit (FTU) method for application of TCS
 For use over smaller area, less than 1 FTU maybe required; advise not to apply beyond the lesion

COMMON TOPICAL FORMULATIONS AND THEIR USAGE	
Topical formulation	Key aspects of usage
Cream	Emulsion of oil and water; preferred for oozy/wet lesions
Ointment	Semi-solid, greasy, occlusive; preferred for better penetration, especially over thick keratotic lesions
Gel	Aqueous or alcoholic monophasic emulsion Liquefies upon contact with skin Preferred for greater cosmetic acceptance, and hairy areas
Lotion	Usually thicker than a solution and likely to contain oil/water/alcohol Use lotions over hairy areas and larger body surface areas
Aerosol foam/spray	A solution with pressurized propellant; alternative to lotion
Powder	Solid, for example, talc/corn starch; doubtful penetration/efficacy

DOSE AND AMOUNT Educate the patient about the optimum quantity (in grams) of TCS required A single application to the whole body of an adult will require 20 to 30 g of product (cream/ointment/lotion) An area of one hand (palm and digits) will require 0.3 g per application No more than 45 g/week of potent or 100 g/week of a moderately potent TCS should be applied Treatment under occlusion should be avoided; only prescribed by specialists



FEW ACCEPTABLE COMBINATIONS WITH TCS

Should be used only in specific situations and under strict supervision

- •TCS+ Fusidic acid 2% cream/ointment (for
- impetiginized eczematous lesions) •TCS + Salicylic Acid (3-6%) ointment (for thick
- hyperkeratotic eczema/psoriasis) · Topical Calcipotriene-TCS (for mild to moderate psoriasis)
- Hydroquinone 2% + Tretinoin 0.025% Fluocinolone Acetonide 0.1% Cream (use with great caution in melasma - high abuse potential)





RATIONAL TOPICAL COMBINATIONS FOR ACNE

- · Clindamycin 1%+Tretinoin 0.025% gel
- · Adapalene 0.1% +Clindamycin phosphate 1%
- Clindamycin 1% + Benzoyl peroxide
- Adapalene 0.1% + Benzoyl peroxide 2.5% gel

GENERAL PRINCIPLES FOR TOPICAL ANTIBIOTIC USE IN ACNE

- Benzoyl peroxide (BPO) alone, or in combinations with Retinoids/ Clindamycin are effective for mild acne, or in conjunction with a topical retinoid, or systemic antibiotic therapy for moderate to severe acne
- BPO is effective in the prevention of bacterial resistance and is recommended for patients on topical or systemic antibiotic therapy
- · Topical antibiotics like Clindamycin are effective acne treatments, but are not recommended as monotherapy because of the risk of bacterial resistance

MOISTURIZERS

- One of the most commonly applied topical preparations for normal skin care and in diseased skin to improve barrier function of skin
- Moisturizer alone are therapeutic in conditions like eczema and psoriasis
- Bland, fragrance-free moisturizer should be preferred
- Moisturizers in common use white soft paraffin/light liquid paraffin, glycerin with water, coconut oil

GENERAL PRINCIPLES FOR TOPICAL SUNSCREEN USE

- · For photosensitive dermatoses like lupus erythematosus, liberal uniform film of sunscreen (2 mg/cm²) should be applied on sun-expoxed sites, and application should be atleast 15 minutes before sun
- Routine topical sunscreen use is not essential except in special situations with intense, prolonged sun exposure, such as mountaineering

● TOPICAL STEROIDS ARE A DOUBLE EDGED SWORD - USE JUDICIOUSLY

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information: (stw.lemr.org.lm) for more information.

©Department of Health Research, Ministry of Health & Family Welfare, Covernment of India.

© 2024 JEFI **S96**